Tom Wickham, Ph.D., Chief Scientific Officer

Oct. 13 | 1:45pm | BlueRock Therapeutics Ballroom

Boston, MA


In-person Presentation

GentiBio, Inc., is an emerging biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio’s proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overactivity and/or malfunctioning of the immune system.

By using this website you agree to accept our Privacy Policy and Terms & Conditions